Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 to 80 years of any gender, with a life expectancy of more than 6 months.
• People with a laboratory-confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) that tests positive for both the CD20 and CD5 proteins on the cancer cells.
• People who have not previously received any treatment for DLBCL, such as chemotherapy, targeted therapy, immunotherapy, or surgery (except for a biopsy or palliative radiotherapy to relieve symptoms).
• People with at least one measurable area of disease: a lymph node lesion longer than 1.5 cm, or a lesion in another part of the body longer than 1.0 cm.
• People with stage III or IV disease and an IPI score between 0 and 5 (a standard scoring system doctors use to assess lymphoma risk).
• People with a general health status rated 0, 1, or 2 on the ECOG scale, meaning they are able to carry out daily activities with little to no limitation (confirm with trial site).
• People whose blood test results before starting the trial show that bone marrow, liver, kidney, and clotting functions are all within acceptable ranges as defined by the trial.
• People whose heart pumping function (left ventricular ejection fraction) is at least 50% on an echocardiogram (heart ultrasound).
• Women of childbearing age who have a negative pregnancy test within 7 days before joining, and who agree to use effective contraception during the trial and for at least 12 months after the last dose.
• Men who agree to use effective contraception during the trial and for at least 3 months after the last dose.
• People who are able to understand the trial and willing to sign a written consent form.

Who may not be able to join:

• People who have had lymphoma involving the brain or spinal cord (central nervous system), either now or in the past.
• People with specific subtypes of large B-cell lymphoma that are excluded from this trial, including but not limited to primary CNS DLBCL, primary mediastinal large B-cell lymphoma, double-hit DLBCL, Burkitt lymphoma, and several other named subtypes (confirm with trial site for the full list).
• People whose current lymphoma has transformed from another type of lymphoma, such as follicular lymphoma or chronic lymphocytic leukaemia.
• People who have previously had an organ transplant or a stem cell transplant.
• People diagnosed with another cancer within the past 5 years, except for certain treated and fully resolved cancers such as early-stage cervical carcinoma in situ, non-melanoma skin cancer, or certain superficial bladder cancers.
• People who have received cytotoxic (cell-killing) drugs for any condition within the past 5 years, or who have ever been treated with an anti-CD20 antibody medication.
• People who have received any monoclonal antibody treatment within the 3 months before the trial starts.
• People who have participated in another interventional clinical trial within the past 3 months.
• People with known allergies or medical reasons that prevent them from taking any of the study medications, including celecoxib (for example, sulfonamide allergy or NSAID-related asthma), rituximab, or any part of the CHOP chemotherapy regimen.
• People taking steroid medications (such as prednisone) at a dose above 30 mg per day for reasons unrelated to lymphoma symptom control.
• People who have had major surgery (not including diagnostic procedures) within one month before joining the trial.
• People with serious nervous system conditions, such as a history of progressive multifocal leukoencephalopathy (a severe brain infection).
• People who have received any prior treatment specifically for DLBCL, including chemotherapy, targeted therapy, immunotherapy, curative-intent radiotherapy, or surgery (other than biopsy).
• People who still have unresolved side effects from a previous treatment that are rated above Grade 1 severity, with certain exceptions such as mild nerve problems, hair loss, or well-controlled thyroid or diabetes conditions.
• People who have received a live vaccine within one month before joining the trial.
• People with an active, clinically unstable infection requiring intravenous antibiotics, antivirals, or antifungals within the 7 days before the trial starts.
• People with active hepatitis B (HBV) or active hepatitis C (HCV) infection (those with controlled HBV or HCV may be considered at the treating doctor's discretion after effective antiviral treatment).
• People with HIV infection or AIDS.
• People who are unable to swallow tablets, or who have a condition affecting how the gut absorbs medication.
• People with significant heart conditions, including heart failure, serious heart rhythm problems, a heart attack or unstable chest pain within the past 6 months, a prolonged QTc interval on an ECG, or blood pressure that remains very high despite taking two blood pressure medications.
• People with pulmonary fibrosis, interstitial lung disease, or serious lung problems that cause symptoms or affect lung function.
• People who have had a stroke, blood clot in a deep vein (DVT), or pulmonary embolism within the past 6 months (certain low-risk clotting events may be considered at the investigator's discretion).
• People who require dialysis for kidney failure, or who have a history of nephrotic syndrome.
• People with a current or past autoimmune disease that requires treatment, except for well-controlled thyroid conditions or type 1 diabetes.
• People with a history of alcoholism or drug abuse.
• People who are pregnant or breastfeeding, or people who are able to have children but are unwilling to use effective contraception.
• People considered ineligible by the trial investigator for any other medical or safety reason.

Important: Always verify eligibility with the trial site directly before applying.